BioSig Technologies Reinvests in Lafayette College’s InternShift Progam
November 20 2018 - 8:00AM
BioSig Technologies, Inc. (NASDAQ: BSGM), a medical
device company developing a proprietary biomedical signal
processing platform designed to address an unmet technology need
for the $4.6 billion electrophysiology (EP) marketplace, today
announced that the Company’s Founder, Chairman & CEO Kenneth
Londoner is making a gift to Pennsylvania-based Lafayette College
in order to support the school’s growing internship program.
Mr. Kenneth L. Londoner ’89, Chairman and CEO of BioSig
Technologies, Inc, was the founding alumnus to help start the
school’s transformative InternShift program in 2014. Together with
the College, BioSig pioneered and successfully developed a highly
immersive internship experience which gives students an opportunity
to enhance their professional interests in an entrepreneurial
environment. During their summers at BioSig, Lafayette students
work on a range of advanced projects, from researching novel
therapies and clinical study breakthroughs, to preparing business
plans and stock pitch decks, to analyzing international healthcare
landscapes and policy standards. To address the ongoing student
debt crisis, interns get paid to offset their living expenses and
tuition fees. “We are very passionate about providing our future
generations with exciting opportunities to launch their careers. We
hope to encourage our interns to try new things and learn real
valuable work skills in anticipation of joining a rapidly changing
work environment. Lafayette College is doing a tremendous job in
connecting their students with the opportunities to learn
applicable skills that are valuable in current and future work
endeavors, and we are very happy to provide both our employment and
financial support to such a great cause,” commented Kenneth L.
Londoner, Chairman and CEO of BioSig Technologies, Inc.
“BioSig Technologies’ unique InternShift experience sets an
aspirational standard for all employers. Thank you for providing
these immersive experiences for so many Lafayette students. You
challenged others to join BioSig Technologies in preparing the next
generation of employees to make a difference for our world,”
commented Mrs. Alison R. Byerly, President of Lafayette
College.
About Lafayette College Lafayette College is a
private liberal arts college based in Easton, Pennsylvania. Founded
in 1826, the College offers a Bachelor of Arts in 37 fields and a
Bachelor of Science in 14 fields, including 4 in engineering.
Lafayette College lists Diversity & Inclusion, Sustainability
and Community Engagement as its core values. The student body comes
from 48 countries.
About BioSig Technologies BioSig Technologies
is a medical technology company developing a proprietary biomedical
signal processing platform designed to improve the
electrophysiology (EP) marketplace (www.biosigtech.com). Led by a
proven management team and a veteran, independent Board of
Directors, Los Angeles-based BioSig Technologies is preparing to
commercialize its PURE EP™ System. The technology has been
developed to address an unmet need in a large and growing
market.
The Company’s first product, PURE EP™ System, is a novel cardiac
signal acquisition and display system which is engineered to assist
electrophysiologists in clinical decision- making during procedures
to diagnose and treat patients with abnormal heart rates and
rhythms. BioSig’s main goal is to deliver technology to improve
upon catheter ablation treatments for the prevalent and potentially
deadly arrhythmias, Atrial Fibrillation and Ventricular
Tachycardia. BioSig has partnered with Minnetronix on technology
development and has received FDA 510(k) clearance for the PURE EP™
System in August 2018.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward-looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) our inability to manufacture our products and
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Contact:
Natasha Drapeau
BioSig Technologies, Inc.
Executive Vice President
12600 Hill Country Blvd R-275
Austin, TX 78738
ndrapeau@biosigtech.com
512-329-2643
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024